Biomarker · Gene alteration

EGFR T790M

EGFR exon 20 point mutation p.T790M detected in tumor tissue or plasma; an acquired resistance mutation to earlier-generation EGFR inhibitors used as a predictive marker for third-generation agents.

CI-BIO-00000011EGFR graph →NCIt C98503

Also calledp.T790M · gatekeeper mutation · c.2369C>T

Derived

Associated cancers (5)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Lung Non-Small Cell Carcinoma	27	25	2	—	5 / 10 / 2 / 9 / 1
Lung Adenocarcinoma	6	6	—	—	0 / 1 / 5 / 0 / 0
Malignant Lung Neoplasm	1	1	—	—	0 / 0 / 0 / 1 / 0
Malignant Neoplasm	1	1	—	—	0 / 0 / 0 / 1 / 0
Pancreatic Adenocarcinoma

Derived

Drugs with predictive evidence (13)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
OsimertinibSmall Molecule	13	12	1	A	11 / 1	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Pancreatic Adenocarcinoma
GefitinibSmall Molecule	7	—	7	B	0 / 7

Curated evidence

Predictive evidence items (34)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–34 of 34 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR T790M28
Erlotinib +

Regulatory

Approvals mentioning the linked drugs (190)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

EGFR Exon 19 Deletion + EGFR T790M2
Osimertinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	1	accepted	EID1397 Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After fur… (full text at CIViC) PMID 26181354 · Yu et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID11598 This phase 3 trial (NCT02151981) involved 419 patients with EGFR T790M mutant NSCLC who progressed after first-line EGFR inhibitor therapy (gefitinib, erlotinib, or afatinib) and were either treated w… (full text at CIViC) PMID 27959700 · Mok et al., 2017 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.	approved	May 22, 2023	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.	approved	May 22, 2023	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.	approved	May 22, 2023	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.	approved	May 22, 2023	openfda
Pemetrexed	US FDA	Lung Non-Small Cell Carcinoma	Limitations of Use: PEMRYDI RTU is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.	approved	May 22, 2023	openfda
Pemetrexed	US FDA	Pleural Malignant Mesothelioma	initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.	approved	May 22, 2023	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2022-12-14 (see label)	approved	Dec 14, 2022	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2022-11-22 (see label)	approved	Nov 22, 2022	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2022-11-22 (see label)	approved	Nov 22, 2022	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2022-11-22 (see label)	approved	Nov 22, 2022	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2022-08-31 (see label)	approved	Aug 31, 2022	openfda
Pemetrexed	US FDA	Lung Non-Small Cell Carcinoma	Limitations of Use : Pemetrexed Injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.	approved	Jun 22, 2022	openfda
Pemetrexed	US FDA	Pleural Malignant Mesothelioma	Initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.	approved	Jun 22, 2022	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC).	approved	Jun 22, 2022	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	As a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.	approved	Jun 22, 2022	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	As a single agent for the maintenance treatment of patients with locally advanced or metastatic, non -squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.	approved	Jun 22, 2022	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.	approved	May 26, 2022	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.	approved	May 26, 2022	openfda
Pemetrexed	US FDA	Lung Non-Small Cell Carcinoma	Limitations of Use: Pemetrexed Injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.	approved	May 26, 2022	openfda
Pemetrexed	US FDA	Pleural Malignant Mesothelioma	initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.	approved	May 26, 2022	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.	approved	May 26, 2022	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.	approved	May 26, 2022	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.	approved	Aug 21, 2020	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.	approved	Aug 21, 2020	openfda
Pemetrexed	US FDA	—	in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.	approved	Aug 21, 2020	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.	approved	Aug 21, 2020	openfda
Pemetrexed	US FDA	Lung Non-Small Cell Carcinoma	Limitations of Use: Pemetrexed Injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.	approved	Aug 21, 2020	openfda
Pemetrexed	US FDA	Pleural Malignant Mesothelioma	initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.	approved	Aug 21, 2020	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).	approved	Feb 8, 2020	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations.	approved	Feb 8, 2020	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	as a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy.	approved	Feb 8, 2020	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.	approved	Feb 8, 2020	openfda
Pemetrexed	US FDA	Lung Non-Small Cell Carcinoma	Limitations of Use : PEMFEXY is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.	approved	Feb 8, 2020	openfda
Pemetrexed	US FDA	Pleural Malignant Mesothelioma	in combination with cisplatin for the initial treatment, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.	approved	Feb 8, 2020	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2019-01-30 (see label)	approved	Jan 30, 2019	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2018-06-04 (see label)	approved	Jun 4, 2018	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2012-10-17 (see label)	approved	Oct 17, 2012	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2011-11-18 (see label)	approved	Nov 18, 2011	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2011-03-17 (see label)	approved	Mar 17, 2011	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2009-07-02 (see label)	approved	Jul 2, 2009	openfda
Pemetrexed	US FDA	—	Efficacy supplement 2008-09-26 (see label)	approved	Sep 26, 2008	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.	approved	Feb 4, 2004	openfda
Pemetrexed	US FDA	Pleural Malignant Mesothelioma	initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.	approved	Feb 4, 2004	openfda
Pemetrexed	US FDA	Lung Non-Small Cell Carcinoma	Limitations of Use: ALIMTA is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.	approved	Feb 4, 2004	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.	approved	Feb 4, 2004	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.	approved	Feb 4, 2004	openfda
Pemetrexed	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.	approved	Feb 4, 2004	openfda

Associated cancers (5)

Drugs with predictive evidence (13)

Predictive evidence items (34)

Approvals mentioning the linked drugs (190)

Active trials (271)

Linked publications (32)